TapImmune Inc.
50 N. Laura Street
Jacksonville, FL 32202
(904) 677-3595
www.TapImmune.com

Company Overview

TapImmune Inc. (NASDAQ: TPIV) is a leader in the immunotherapy of women's cancers. The Company is advancing its two clinical-stage T-cell vaccine candidates in multiple Phase 2 and Phase 1b/2 clinical trials that address the unmet need in ovarian and breast cancer. The company is working in collaboration with industry and clinical leaders such as the Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca, including two Phase 2 studies that are fully funded by ~$17 million in non-dilutive grants from the U.S. Department of Defense. The company expects to reach several clinical milestones over the next 18-months, as well as drive significant value through successful out-licensing of its proprietary protein expression technology, PolyStart™, which enhances the potency of DNA-based vaccines.

EQUITY OVERVIEW

NASDAQ: TPIV

Price (5/15/17): $3.98

Shares Outstanding (4/6/17): 8.4

Market Cap (5/15/17): ~$33.4 M

Cash Balance (3/31/17): ~ $5.9 M

UPCOMING MILESTONES

Q3 2017: Long-term survival and immunogenicity data for patients treated with TPIV 200 in a completed Phase 1 study

Q4 2017: Phase 2 interim analysis for TPIV 200 Combo with AstraZeneca's checkpoint inhibitor in platinum-resistant ovarian cancer

Q4 2017: Complete enrollment in Phase 2 dosing study of TPIV 200 in triple-negative breast cancer; report interim results

2H 2017: Initiate two Phase 2, Mayo Clinic-sponsored, U.S. DoD-funded clinical studies in triple-negative and HER2/neu+ breast cancer

WORKING WITH PRESTIGIOUS COLLABORATORS

MAYO CLINIC

AstraZeneca

Memorial Sloan Kettering Cancer Center

Pipeline: Multiple Phase 2 Trials Ongoing



Pipeline/Investment Highlights

Immunotherapy is Leading Growth in >$100 B Cancer Drug Market

The global market for cancer drugs is projected to top $150 billion by 2020 (IMS Health). Much of the growth is being driven by consistent innovations in cancer immunotherapy, which is expected to continue growing to $75.8 billion by 2022 across major markets (GBI Research, 2016). TapImmune is poised to capture part of this large and highly active market with its next-generation T-cell vaccine technology and unique focus on women's immune health. Lead programs are summarized below.

Phase 2: Advanced Platinum-Resistant Ovarian Cancer – High Unmet Need

Currently enrolling at multiple Memorial Sloan Kettering clinical sites, this study will evaluate the company's TPIV 200 vaccine in combination with AstraZeneca's immune checkpoint inhibitor, durvalumab. The groundbreaking study is >50% enrolled with patients without treatment options and very poor prognosis due to tumor resistance to platinum-based chemotherapy. An interim data review is planned for Q4 2017.

Phase 2: FDA Fast Tracked Study in Platinum-Sensitive Ovarian Cancer

Blinded, randomized, controlled study currently enrolling women with ovarian cancer that responded to recent platinum-based therapy who are at risk of a second recurrence. The two-arm study will evaluate TPIV 200 as a maintenance therapy to potentially reduce the rate of cancer recurrence compared to placebo. FDA Fast Track may accelerate review.

Phase 2: Dosing Study in Advanced Triple-Negative Breast Cancer

Blinded, randomized, study to determine the optimal vaccine dosing/regimen to maximize immune response in women with triple-negative breast cancer. The four-arm study will examine two doses of TPIV 200, with/without cyclophosphamide immune priming, as well as employ a booster vaccine every six months without a recurrence. No issues were uncovered by a recent independent safety review and the study is expected to complete enrollment by year end 2017, with top-line data anticipated in early 2018.

PolyStart™: Internal Development for Cancer; Out-licensing Opportunity

Proprietary vaccine technology that directs enhanced expression of multiple peptide antigens from a single DNA vector, at levels 4-fold or greater compared to conventional expression systems. PolyStart is versatile and dynamic, able to direct synergistic immune responses against cancer or viral infections. TapImmune is seeking opportunities to monetize PolyStart through strategic out-licensing or collaboration.